FREE BETA HCG

The double marker test, conducted by Hypro Diagnostics, plays a crucial role in early pregnancy by evaluating the potential risk of Down’s syndrome and other chromosomal anomalies in the developing fetus. This procedure involves analyzing the levels of free beta subunit of human chorionic gonadotrophin (HCG) and pregnancy-associated plasma protein-A (PAPP-A) in the blood of pregnant women during the first trimester. The distinctive patterns of free beta HCG levels, along with considerations such as maternal age and ultrasonographic assessment of nuchal translucency between the 11th and 14th weeks of pregnancy, collectively contribute to a comprehensive risk assessment. This advanced approach not only facilitates the early identification of possible chromosomal anomalies but also showcases the impressive synergy of medical science and technology in safeguarding the health of both the expectant mother and the developing fetus, under the expertise of Hypro Diagnostics.